跳至主要内容
临床试验/NCT01592253
NCT01592253Unknown不适用

Investigation of the Safety and Immunologic Biomarker After Conversion From Calcineurin Inhibitor to Rapamune in Stable Renal Transplant Recipient

Seoul St. Mary's Hospital1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2012年5月最近更新:
适应症
相关药物

试验速览

阶段
不适用
入组人数
50
试验地点
1
主要终点
biopsy proven acute rejection

研究概览

简要总结

For patients who meet the inclusion criteria and who agree to participate in this study, the investigators sampled peripheral blood 10cc and performed the analysis for immunologic profile just before the conversion of immune suppressant. At 1 month, 6 month, and 1 year from the conversion of Immune suppressant (CNI to rapamune), the investigators performed tha analysis fo immune profile again. During the study period, the interval of the visit of subclinic and the kinds of laboratory test (Blood and urine test) would not change compared to before the start of this study.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • Renal transplant recipient who has passed at least 10 years
  • No acute rejection episode during the previous 6 months
  • No change of prescription of immune suppressants
  • Normal allograft function (MDRD eGFR > 80 mL/min/1.73 m2)
  • Change of allograft function less than 10 % of baseline value durant the previous 1 year
  • No proteinuria and hematuria

排除标准

  • Patients who donut want to participate in this study
  • Patients who should continue immune suppressant due to another cause (e/g combined autoimmune disease)

结局指标

主要结局

biopsy proven acute rejection

时间窗: Study duration is 12 months

Number of episode of biopsy proven acute rejection

次要结局

  • Serum Creatinine, MDRD eGFR(Study duration is 12 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

ChulWoo Yang

professor

Seoul St. Mary's Hospital

研究点 (1)

Loading locations...

相似试验